Jounce Therapeutics to Present at Upcoming Investor Conferences in September
30 août 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development
15 août 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2017 Financial Results
09 août 2017 06h30 HE
|
Jounce Therapeutics, Inc.
- Presented Phase 1 data from ICONIC study of JTX-2011 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - - Initiated Phase 2 portion of ICONIC study evaluating JTX-2011 in...
Jounce Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9, 2017
02 août 2017 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled...
Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO Annual Meeting
05 juin 2017 09h00 HE
|
Jounce Therapeutics, Inc.
-- ICOS Agonist Antibody Well Tolerated Alone and as Combination Immunotherapy -- -- Phase 2 Monotherapy Cohorts Are Currently Enrolling Using ICOS Biomarker Patient Enrichment -- CAMBRIDGE,...
Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting
17 mai 2017 17h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports First Quarter 2017 Financial Results
09 mai 2017 08h00 HE
|
Jounce Therapeutics, Inc.
- Completed upsized initial public offering raising $117.1 million in gross proceeds -- Presented preclinical data supporting ongoing Phase 1/2 ICONIC study -- Initiated Phase 2 portion of ICONIC...
Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
20 avr. 2017 16h01 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
31 mars 2017 16h01 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program
22 mars 2017 16h01 HE
|
Jounce Therapeutics, Inc.
-- Invited oral presentation on JTX-2011 preclinical data -- -- Poster presentation on single agent and combination trial design -- CAMBRIDGE, Mass., March 22, 2017 (GLOBE NEWSWIRE) -- Jounce...